MyFinsight
Home
Blog
About
Proceeds from sale of
common stock under...
$140,722,254
(12643.21%↑ Y/Y)
Proceeds from sale of
common stock under atm...
$14,037,289
Proceeds from exercise of
stock warrants
$441,202
Proceeds from exercise of
stock options
$11,160
(91.62%↑ Y/Y)
Proceeds from the sale of
investments
$10,240,000
something is missing
$4,768,350
Net cash provided by
financing activities
$155,282,998
(13888.00%↑ Y/Y)
Net cash used in
investing activities
$2,669,664
(1466.65%↑ Y/Y)
Effect of foreign
currency on cash
$24,665
(-31.75%↓ Y/Y)
Canceled cashflow
$12,338,686
Net change in cash
and cash...
$146,241,822
(2519.62%↑ Y/Y)
Canceled cashflow
$11,735,505
Stock-based compensation
$978,140
(-30.16%↓ Y/Y)
Depreciation
$90,993
(-5.85%↓ Y/Y)
Amortization of right of use
asset
$39,891
(-5.85%↓ Y/Y)
Prepaid expenses and
other current assets
-$12,044
(-108.25%↓ Y/Y)
Purchase of investments
$12,317,643
Purchase of property and
equipment
$21,043
(-89.23%↓ Y/Y)
Net cash used in
operating activities
-$11,735,505
(-67.77%↓ Y/Y)
Canceled cashflow
$1,121,068
Net loss
-$11,557,002
(-3.51%↓ Y/Y)
Accounts payable and
accrued expenses
-$1,225,630
(-256.55%↓ Y/Y)
Realized gain on
available-for-sale securities
$38,683
Operating lease liability
-$35,983
(-12.56%↓ Y/Y)
Back
Back
Cash Flow
Immix Biopharma, Inc. (IMMX)
Immix Biopharma, Inc. (IMMX)
source: myfinsight.com